OakChart

Atara Biotherapeutics Inc

ATRAHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 1:56 PM ET

8.37+0.27 (3.33%)
2026-11-11 19:59 CET
Market cap
81.31 USD m
Revenue, TTM
3.96 USD m
Net income, TTM
-14.61 USD m
Free cash flow, TTM
-12.99 USD m
EPS diluted, TTM
-1.23
P/E
-
Compare

Price

ATRA against its 20, 50 and 200-day averages
2050200beatearnings
6.008.0010.0012.001.5M3.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ATRAclose 8.3720-day 8.5850-day 9.01200-day 7.818.37

56.3% under the 52-week high of 19.15 on 5 Jan 2026. 52-week low 3.92 on 23 Feb 2026. Last 15 sessions, 29.2% high to low

Profile

ATRA
52-week range, 29% of the way up
3.9219.15

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Employees14
IPOOct 16, 2014
Beta0.31
ATR, 14d0.57
Rel volume0.22
Short float4.28%
Insider own30.97%
Inst own47.34%

Snapshot

6 groups

Valuation

Index-
Market Cap84.02M
Enterprise Value124.33M
Income-14.61M
Sales3.96M
Book/sh-3.72
Cash/sh0.99
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees14
IPOOct 16, 2014

Ratios

P/E-
Forward P/E8.55
PEG-
P/S21.22
P/B-
P/C8.47
P/FCF-
EV/EBITDA-
EV/Sales31.40
Quick Ratio1.72
Current Ratio1.72
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.23
EPS next Y0.98
EPS next Q-0.09
EPS this Y-123.02%
EPS next Y265.44%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y23.85% -
EPS Y/Y TTM-253.97%
Sales Y/Y TTM-97.39%
EPS Q/Q54.16%
Sales Q/Q-64.55%
EarningsNov 10 AMC
EPS/Sales Surpr.-12.95% 53.00%

Ownership

Insider Own30.97%
Insider Trans10.11%
Inst Own47.34%
Inst Trans-1.94%
ROA-59.93%
ROE-
ROIC-144.12%
Gross Margin82.75%
Oper. Margin-358.39%
Profit Margin-368.58%
SMA20-2.50%
SMA50-7.12%
SMA2007.16%
Trades-

Technical

Shs Outstand10.19M
Shs Float6.93M
Short Float4.28%
Short Ratio7.44
Short Interest0.30M
52W High19.15 -56.28%
52W Low3.92 113.52%
Volatility6.81% 6.79%
ATR (14)0.57
RSI (14)46.72
Beta0.31
Rel Volume0.22
Avg Volume39.89K
Volume6,101

Performance

Perf Week0.00%
Perf Month-10.05%
Perf Quarter-1.65%
Perf Half Y-20.13%
Perf YTD-53.73%
Perf Year-33.36%
Perf 3Y45.69%
Perf 5Y-98.09%
Perf 10Y-98.34%
Recom1.50
Target Price13.67
Prev Close8.10
Price8.37
Change %3.33%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
May 08, 2026UpgradeCCanaccord GenuityHold → Buy$13+55.3%
Jan 13, 2026DowngradeCCanaccord GenuityBuy → Hold$6-28.3%
Nov 09, 2023DowngradeMMizuhoBuy → Neutral$31 → $1-88.1%
Nov 09, 2023DowngradeHH.C. WainwrightBuy → Neutral
Nov 09, 2023DowngradeEEvercore ISIOutperform → In-line
Jul 20, 2022DowngradeCCitigroupNeutral → Sell$8 → $3-64.2%
Jul 13, 2022DowngradeSStifelBuy → Hold$16 → $5-40.3%
Jul 13, 2022DowngradeJJP MorganOverweight → Neutral$10+19.5%
May 10, 2022DowngradeCCitigroupBuy → Neutral$15 → $8-4.4%
May 13, 2021UpgradeJJP MorganNeutral → Overweight$23 → $29+246.5%

Peers

Mkt cap
TickerCompanyMkt cap
CRBUCaribou Biosciences Inc41.86M
ALLOAllogene Therapeutics Inc309.57M
TVGNTevogen Inc38.55M
CLLSCellectis ADR96.56M
MRKRMarker Therapeutics Inc15.68M
TCRXTscan Therapeutics Inc12.52M
ACETAdicet Bio Inc28.17M
FATEFate Therapeutics Inc201.60M
NKTXNkarta Inc102.89M
IPSCCentury Therapeutics Inc310.55M

Insider trading

latest 14 of 22
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Cherry Brian NDirectorSep 04 '26Buy9.60104,166999,994166,486Sep 04 06:20 PM
Nguyen AnhCoDirectorAug 17 '26Proposed Sale8.365,06242,318Aug 26 07:47 PM
Nguyen AnhCoPresident and CEOAug 17 '26Sale8.085,06240,883132,775Aug 26 07:45 PM
Nguyen AnhCoPresident and CEOMay 18 '26Sale9.135,24147,845137,837May 20 05:24 PM
Grant-Huerta YaninaChief Accounting OfficerMay 18 '26Sale9.132,41422,03649,636May 20 05:24 PM
Nguyen AnhCoDirectorMay 18 '26Proposed Sale10.485,98162,681May 18 04:45 PM
Grant-Huerta YaninaOfficerMay 18 '26Proposed Sale10.482,75428,862May 18 04:44 PM
Panacea Innovation Ltd10% OwnerMay 07 '26Sale10.10313,4463,165,0211,011,000May 11 06:45 PM
EcoR1 Capital, LLC10% OwnerMay 07 '26Buy9.35507,4074,744,2551,552,000May 11 05:34 PM
Panacea Innovation Ltd10% OwnerMay 07 '26Proposed Sale10.10313,4463,165,021May 07 08:30 PM
Panacea Innovation Ltd10% OwnerMar 17 '26Option Exercise0.00259,16326307,899Mar 19 04:30 PM
Grant-Huerta YaninaChief Accounting OfficerMar 02 '26Sale5.082,10410,69131,750Mar 04 04:28 PM
Nguyen AnhCoPresident and CEOMar 02 '26Sale5.092,99615,23761,978Mar 04 04:28 PM
Nguyen AnhCoDirectorMar 02 '26Proposed Sale5.423,35518,184Mar 02 06:25 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.150-0.133-0.1451.220.804
2026Q22026-08-12-0.320-0.315-0.3220.630.552
2026Q12026-05-12-0.290-0.330-0.2940.522.903
2025Q42026-03-16-0.250-0.176-0.4651.643.374
2025Q32025-11-12-0.320-0.666-0.3173.453.734
2025Q22025-08-110.190-0.0660.19417.587.352
2025Q12025-05-153.500-1.9803.50398.105.673
2024Q42025-03-07-1.190-2.861-1.18732.7520.587
2024Q32024-11-12-2.930-1.888-2.93540.1928.664
2024Q22024-08-12-3.100-2.238-3.10128.6437.095
2024Q12024-05-09-5.750-6.417-5.64627.3624.693
2023Q42024-03-28-14.000-11.125-13.9764.252.566
2023Q32023-11-01-16.500-15.570-16.4002.145.098
2023Q22023-08-08-17.000-16.405-16.9160.964.369
2023Q12023-05-08-18.000-9.265-17.9791.2332.018
2022Q42023-02-08-18.000-12.993-18.0690.2234.016

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-141.75-140.53-5.6710.000.00
2020FY-103.75-97.193-103.630.0015.00
2021FY-90.750-83.345-90.78220.3441.63
2022FY-56.000-50.035-55.96263.5796.77
2023FY-65.250-61.125-65.1788.576.77
2024FY-11.410-7.333-11.405128.94116.64
2025FY2.5702.8672.570120.77121.72
2026FY--0.592--3.52
2027FY-0.979--45.65
2028FY-0.438--38.24
2029FY-1.693--69.45
2030FY-2.686--92.19

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-112001.350.702.00
2026Q4S2026-11-102001.350.702.00
2026Q4S2026-10-272001.350.702.00
2026Q4S2026-08-312101.350.702.00
2026Q4S2026-08-132111.350.702.00
2026Q4S2026-07-292011.050.102.00
2026Q4S2026-06-172021.050.102.00
2026Q4S2026-05-292013.550.107.00
2026Q4S2026-05-153016.830.1013.40
2026Q4S2026-05-133008.876.2013.40
2026Q4S2026-03-273008.876.2013.40
2026Q4S2026-03-172009.806.2013.40
2026Q4S2026-02-1810013.4013.4013.40
2026Q4S2025-11-121004.154.154.15

Estimate history

EPS, annual-100.033-131.645-5.671-103.626-90.782-55.962-65.178-11.4052.57-1.2264
Period201720182019202020212022202320242025TTM
EPS, quarterly-2.935-1.1873.5030.194-0.317-0.465-0.294-0.322-0.145
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000020.3463.5738.573128.94120.7723.96
Period201720182019202020212022202320242025TTM
Sales, quarterly40.1932.75398.14917.5753.4531.5950.5160.631.224
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.2291.83856.8063.3353.6673.8374.2585.8597.32410.188
Period201720182019202020212022202320242025MRQ
Shares, quarterly5.745.8595.9246.9787.217.3248.5129.44310.188
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3.96120.77128.948.5763.5720.340.000.000.00
Cost of Goods Sold Incl. D&A0.6821.2121.018.8914.5711.389.878.113.78
Gross Profit3.2899.56107.93-0.3149.018.96-9.87-8.11-3.78
Selling, General and Administrative Excl. Other17.4949.79186.26268.96323.55349.42299.19287.58233.33
Research and Development-27.50147.73219.17269.11282.00244.65216.10167.46
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-14.2149.77-78.33-269.28-274.55-340.46-309.05-295.68-237.11
Interest Expense-3.794.625.29-----
Unusual Expense2.0116.515.116.735.96----
Net Income Before Taxes-14.6132.72-85.42-276.11-228.29-340.10-306.61-290.96-230.74
Income Taxes0.000.03-0.010.010.010.050.010.01-0.04
Consolidated Net Income-14.6132.69-85.40-276.13-228.30-340.14-306.62-290.98-230.70
Net Income From Continuing Operations-14.6132.69-85.40-276.13-228.30-340.14-306.62-290.98-230.70
Net Income-14.6132.69-85.40-276.13-228.30-340.14-306.62-290.98-230.70
EPS (Recurring)-0.863.48-10.93-64.07-54.94-90.78-103.63-5.67-131.64
EPS (Basic, Before Extraordinaries)-1.232.61-11.41-65.18-55.96-90.78-103.63-5.67-131.64
EPS (Diluted)-1.232.57-11.41-65.18-55.96-90.78-103.63-5.67-131.64
EBITDA-14.1251.89-75.63-264.45-259.98-329.08-299.19-287.58-233.33
Non-Operating Income (Expense)3.523.252.645.1852.220.372.454.726.37
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.787.7021.3335.8542.5339.3223.0137.7426.72
Price To Sales Ratio-1.900.776.345.2672.58---
Gross Margin82.7582.4483.71-3.6577.0844.05---
Operating Margin-358.3941.21-60.75-3,140.98-431.86-1,673.85---
Net Margin-368.5827.07-66.23-3,220.88-359.12-1,672.28---
Shares Outstanding10.197.325.864.263.843.673.3356.811.84
Market Capitalization81.3181.3176.6652.27311.201,444.731,636.5923,389.871,596.34

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.220.630.521.593.4517.5798.1532.75
Cost of Goods Sold Incl. D&A0.270.190.120.100.120.5520.446.79
Gross Profit0.960.440.391.493.3417.0277.7125.96
Selling, General and Administrative Excl. Other3.934.393.765.416.8812.3029.0938.16
Research and Development1.101.340.16-2.916.3719.0828.72
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.97-3.95-3.37-3.92-3.554.7248.62-12.20
Interest Expense-0.190.830.890.910.971.021.02
Unusual Expense0.000.770.001.250.031.529.810.00
Net Income Before Taxes-2.23-4.83-4.14-3.41-4.282.3938.01-12.71
Income Taxes0.000.000.000.000.030.000.00-0.02
Consolidated Net Income-2.23-4.83-4.14-3.41-4.302.3938.01-12.69
Net Income From Continuing Operations-2.23-4.83-4.14-3.41-4.302.3938.01-12.69
Net Income-2.23-4.83-4.14-3.41-4.302.3938.01-12.69
EPS (Recurring)-0.15-0.29-0.29-0.35-0.320.284.14-1.19
EPS (Basic, Before Extraordinaries)-0.15-0.32-0.29-0.47-0.320.203.53-1.19
EPS (Diluted)-0.15-0.32-0.29-0.47-0.320.193.50-1.19
EBITDA-2.97-3.94-3.34-3.87-3.514.9650.41-11.70
Non-Operating Income (Expense)0.740.080.052.650.210.170.230.51
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.360.310.591.520.972.214.214.62
Price To Earnings Ratio--1.628.25----
Price To Sales Ratio-27.862.881.101.280.500.321.10
Gross Margin78.3569.6875.9793.4896.6796.8579.1879.25
Operating Margin-242.65-627.46-652.91-245.64-102.7226.8649.53-37.26
Net Margin-182.11-767.30-803.29-213.54-124.6213.5838.73-38.75
Shares Outstanding10.199.448.517.327.216.985.925.86
Market Capitalization81.31103.4438.68130.43100.6452.4634.8076.66

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments8.4842.6451.87242.97371.26500.85259.30309.82166.29
Short Term Receivables1.251.4834.1140.220.991.250.000.000.00
Inventories0.0010.659.711.590.000.000.000.000.00
Other Current Assets2.4810.126.1810.3112.3721.1713.6911.665.90
Total Current Assets12.2164.89101.87295.08384.62523.27272.99321.49172.19
Net Property, Plant & Equipment7.1441.1058.7974.3279.9462.8268.1868.5844.13
Total Investments and Advances0.000.000.000.001.201.201.201.201.20
Intangible Assets---0.000.000.000.000.000.00
Deferred Tax Assets1.66--------
Other Assets0.893.104.847.022.370.830.570.570.26
Total Assets21.89109.10165.50376.42468.13588.12342.94391.84217.78
Short Term Debt Incl. Current Port. of LT Debt10.7813.9212.1813.642.751.991.580.490.50
Accounts Payable0.134.373.686.8717.377.127.963.7214.71
Other Current Liabilities4.02116.29126.3658.4185.6773.8027.2035.7712.44
Total Current Liabilities14.92134.57142.2378.92105.7982.9036.7439.9827.65
Long Term Debt42.0270.1445.6958.0625.5513.1914.380.250.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities1.66--------
Other Liabilities1.791.6776.82112.8057.1829.691.0412.7612.27
Total Liabilities60.39206.38264.74249.78188.51125.7852.1652.9839.91
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-38.50-97.28-99.23126.64279.61462.34290.78338.86177.86
Total Shareholders Equity-38.50-97.28-99.23126.64279.61462.34290.78338.86177.86
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-38.50-97.28-99.23126.64279.61462.34290.78338.86177.86
Total Liabilities & Stockholders Equity21.89109.10165.50376.42468.13588.12342.94391.84217.78
Book Value Per Share-5.26-16.60-23.3133.0076.25138.645.12184.36144.70
Tangible Book Value Per Share-5.26-16.60-23.3133.0076.25138.645.12184.36144.70
Full-Time Employees14153225334578437393311185
Price to Book Ratio-2.07-0.84-1.031.665.173.5480.444.712.69
Return on Assets49.91-62.20-101.91-54.06-64.41-65.86-79.20-75.69-49.61
Return on Equity---2,014.86-112.39-91.69-81.43-92.43-89.29-55.37
Return on Invested Capital929.16---123.60-111.46-64.48-95.35-68.03-67.18
Quick Ratio0.820.400.653.723.646.317.438.046.23
Current Ratio0.820.480.723.743.646.317.438.046.23

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-14.6132.69-85.40-276.13-228.30-340.14-306.62-290.98-230.70
Depreciation0.102.125.054.8314.5711.389.878.113.78
Other Funds (Non Cash)2.1718.9942.5962.984.7755.6652.3151.3932.14
Funds from Operations-12.3553.80-37.76-208.32-208.96-273.11-244.44-231.48-194.78
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.64-104.73-30.9615.34-61.4752.5863.69-4.1515.00
Cash from Operating Activities-12.99-50.94-68.72-192.98-270.43-220.52-180.76-235.63-179.77
Capital Expenditures0.000.00-0.25-1.22-4.19-10.58-4.51-5.73-35.92
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.560.950.000.0394.770.000.000.160.00
Purchase or Sale of Investments2.0917.208.87125.06112.3832.84-116.2266.03-160.36
Purchase of Investments-9.49-7.88-19.66-83.65-180.59-301.13-425.87-270.23-466.49
Sale Or Maturity of Investments11.5925.0928.54208.71292.97333.97309.65336.26306.12
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities2.6518.158.62123.87202.9622.26-120.7360.46-196.29
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.6716.3560.183.0623.81105.46429.65195.97365.57
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock8.6716.3560.183.0623.81105.46429.65195.97365.57
Proceedsfrom Stock Options23.4716.3159.952.1421.8998.70422.97188.62340.88
Issuance or Reduction of Debt, Net0.00-0.25-0.89-0.95-0.52-0.25-0.39-0.49-0.53
Change in Long Term Debt0.00-0.25-0.89-0.95-0.52-0.25-0.39-0.49-0.53
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.00-0.25-0.89-0.95-0.52-0.25-0.39-0.49-0.53
Net Financing Active Other Cash Flow-0.01-0.00-0.01-0.1129.79-1.26-1.69-6.70-7.50
Other Financing Activities Uses0.00-0.00-0.01-0.11-0.62-1.26-1.69-6.70-7.50
Cash from Financing Activities8.6516.1059.282.0153.08103.94427.57188.79357.54
Net Change in Cash-1.69-16.69-0.81-67.10-14.39-94.32126.0913.62-18.52
Free Cash Flow-12.99-50.94-68.96-194.20-274.62-231.10-185.27-241.36-215.70
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments9.929.878.368.4813.7122.32
Short Term Receivables0.690.320.001.251.910.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.703.343.812.482.812.45
Total Current Assets11.3113.5312.1712.2118.4324.77
Net Property, Plant & Equipment6.536.736.937.1410.8511.20
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets---1.66--
Other Assets0.760.770.890.890.880.93
Total Assets18.6121.0220.0021.8930.1736.90
Short Term Debt Incl. Current Port. of LT Debt2.192.131.7310.7811.622.81
Accounts Payable0.760.820.640.130.321.76
Other Current Liabilities3.623.893.284.026.129.99
Total Current Liabilities6.576.855.6414.9218.0614.56
Long Term Debt48.0449.2949.8442.0246.9855.65
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.66--
Other Liabilities1.901.891.831.791.761.73
Total Liabilities56.5158.0257.3160.3966.8071.94
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-37.90-37.00-37.31-38.50-36.63-35.04
Total Shareholders Equity-37.90-37.00-37.31-38.50-36.63-35.04
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-37.90-37.00-37.31-38.50-36.63-35.04
Total Liabilities & Stockholders Equity18.6121.0220.0021.8930.1736.90
Book Value Per Share-3.72-3.92-4.38-5.26-5.08-5.02
Tangible Book Value Per Share-3.72-3.92-4.38-5.26-5.08-5.02
Full-Time Employees10--14--
Price to Book Ratio-2.07-2.62-0.90-3.56-2.85-0.83
Return on Assets-59.93-57.62-23.0849.9127.077.52
Return on Invested Capital-21.98-39.33-33.10-96.82-41.5911.58
Quick Ratio1.721.982.160.821.021.70
Current Ratio1.721.982.160.821.021.70

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-2.23-4.83-4.14-3.41-4.302.39
Depreciation0.000.010.030.050.040.24
Other Funds (Non Cash)-0.040.781.80-0.372.362.83
Funds from Operations-2.26-4.04-2.32-3.72-1.915.45
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.390.70-0.75-1.97-7.88-12.77
Cash from Operating Activities-0.88-3.34-3.07-5.70-9.79-7.32
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.560.040.35
Purchase or Sale of Investments0.83-6.630.007.88-2.46-5.42
Purchase of Investments-2.87-6.630.000.00-2.47-5.42
Sale Or Maturity of Investments3.700.000.007.880.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.83-6.630.008.44-2.42-5.07
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.884.832.950.011.0315.30
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.884.832.950.011.0315.30
Proceedsfrom Stock Options0.884.832.9514.821.500.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.010.010.00
Other Financing Activities Uses0.000.000.000.000.00-0.00
Cash from Financing Activities0.884.832.95-0.001.0515.30
Net Change in Cash0.83-5.14-0.122.74-11.162.92
Free Cash Flow-0.88-3.34-3.07-5.70-9.79-7.32

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 128.94M 2025: 120.77M
United States2024: 128.94M 2025: 120.77M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.28%0.3M6.9M41.47K
2026-10-155.05%0.4M6.9M47.89K
2026-09-304.64%0.3M6.9M56.21K
2026-09-155.83%0.4M6.9M64.78K
2026-08-316.17%0.4M6.9M68.77K
2026-08-147.14%0.5M6.7M90.66K
2026-07-318.95%0.5M6.0M1.41M
2026-07-159.63%0.6M6.0M1.43M
2026-06-306.03%0.4M6.0M1.40M
2026-06-158.21%0.5M6.0M1.39M
2026-05-298.14%0.5M6.0M1.53M
2026-05-159.18%0.5M6.0M1.54M
2026-04-306.05%0.3M5.1M226.69K
2026-04-156.54%0.3M4.9M279.29K
2026-03-316.80%0.3M4.8M449.73K
2026-03-136.51%0.3M4.8M441.26K
2026-02-277.78%0.3M4.3M306.34K
2026-02-134.92%0.2M4.3M287.76K
2026-01-306.65%0.3M4.3M285.90K
2026-01-1523.92%1.0M4.3M233.06K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-08-26144Filing for proposed sale of securities under Rule 144.SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-244Statement of changes in beneficial ownership of securities2026-07-22SEC
2026-07-24SCHEDULE 13D/ASEC
2026-07-063Initial statement of beneficial ownership of securities2026-06-26SEC
2026-06-268-KCurrent report2026-06-22SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-153Initial statement of beneficial ownership of securities2026-06-11SEC
2026-06-12S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-128-KCurrent report2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-18144Filing for proposed sale of securities under Rule 144.SEC
2026-05-18144Filing for proposed sale of securities under Rule 144.SEC
2026-05-14SCHEDULE 13D/ASEC
2026-05-13SCHEDULE 13GSEC
2026-05-12424B5SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-05-11SCHEDULE 13D/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09999.99K100
2026-080040.88K1
2026-070000
2026-060000
2026-054.74M13.23M3
2026-040000
2026-030025.93K2
2026-020000
2026-0100489.02K1
2025-120000
2025-110062.23K2

Institutional holders

Manager% owned
EcoR1 Capital, LLC17.22%
ADAGE CAPITAL PARTNERS GP, L.L.C.9.43%
Point72 Asset Management, L.P.7.63%
Redmile Group, LLC4.90%
VANGUARD CAPITAL MANAGEMENT LLC2.74%
MACKENZIE FINANCIAL CORP1.76%
BlackRock, Inc.0.94%
GEODE CAPITAL MANAGEMENT, LLC0.81%
STALEY CAPITAL ADVISERS INC0.50%
VANGUARD FIDUCIARY TRUST CO0.48%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.76%
VANGUARD EXTENDED MARKET INDEX FUND0.92%
Fidelity Extended Market Index Fund0.38%
iShares Micro-Cap ETF0.19%
VIP Disciplined Small Cap Portfolio0.18%
Ultra-Small Company Market Fund0.16%
Fidelity Total Market Index Fund0.12%
Fidelity Series Total Market Index Fund0.11%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.03%
VANGUARD BALANCED INDEX FUND0.03%

OakChart. ATRA. Cached 15 minutes.